Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Oct;34(7):779-85.
doi: 10.1016/j.nucmedbio.2007.03.007. Epub 2007 May 11.

Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies

Michael R Zalutsky  1 , David A Reardon, Oscar R Pozzi, Ganesan Vaidyanathan, Darell D Bigner
Affiliations
Review

Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies

Michael R Zalutsky et al. Nucl Med Biol. 2007 Oct.

Abstract

An attractive feature of targeted radionuclide therapy is the ability to select radionuclides and targeting vehicles with characteristics that are best suited for a particular clinical application. One combination that has been receiving increasing attention is the use of monoclonal antibodies (mAbs) specifically reactive to receptors and antigens that are expressed in tumor cells to selectively deliver the alpha-particle-emitting radiohalogen astatine-211 (211At) to malignant cell populations. Promising results have been obtained in preclinical models with multiple 211At-labeled mAbs; however, translation of the concept to the clinic has been slow. Impediments to this process include limited radionuclide availability, the need for suitable radiochemistry methods operant at high activity levels and lack of data concerning the toxicity of alpha-particle emitters in humans. Nonetheless, two clinical trials have been initiated to date with 211At-labeled mAbs, and others are planned for the near future.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Simplified decay scheme for 211At and properties of 211At α-particles.
Figure 2
Figure 2
Kaplan-Meier survival of all recurrent patients and those with GBM after treatment with 211At-labeled chimeric 81C6 anti-tenascin mAb.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted α-particle therapy. J Nucl Med. 2005;46:199S–204S. - PubMed
    1. Zalutsky MR, Vaidyanathan G. Astaine-211-labeled radiotherapeutics: an emerging approach to targeted alpha particle therapy. Curr Pharm Design. 2000;6:1433–55. - PubMed
    1. Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Zhang D, et al. Targeted alpha therapy for cancer. Phys Med Biol. 2004;49:3703–3712. - PubMed
    1. Akabani G, Carlin S, Welsh P, Zalutsky MR. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: Effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol. 2006;33:333–47. - PubMed
    1. Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, et al. Radiation induced biological bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with α–, β– and Auger Electron emitting radionuclides. J Nucl Med. 2006;47:1007–15. - PubMed

Publication types

MeSH terms